Virus-related liver cirrhosis: Molecular basis and therapeutic options

World Journal of Gastroenterology

Volumn 20, Issue 21, 2014, Pages 6457-6469

  Lin, Ji ^a   Wu, Jian Feng ^a   Zhang, Qi ^a   Zhang, Hong Wei ^a   Cao, Guang Wen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antiviral therapy; Evolution; Hepatic stellate cells; Hepatitis B virus; Hepatitis C virus; Immune cells; Liver cirrhosis; Signaling pathway

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; CIRCULAR DNA; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; ENTECAVIR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LIPOPOLYSACCHARIDE; PROTEIN KINASE R; RIBAVIRIN; TELBIVUDINE; TENOFOVIR DISOPROXIL; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ANTIVIRAL THERAPY; ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; FIBROGENESIS; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MOLECULAR BIOLOGY; PATHOGENESIS; RISK FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TISSUE REPAIR; TREATMENT RESPONSE; VIRUS INFECTION; ANIMAL; CD8+ T LYMPHOCYTE; CYTOLOGY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; MUTATION; NATURAL KILLER CELL; REGENERATION; STELLATE CELL; STEM CELL; VIROLOGY; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; GENOTYPE; HEPACIVIRUS; HEPATIC STELLATE CELLS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION; INTERFERON-ALPHA; INTERLEUKINS; KILLER CELLS, NATURAL; LIVER CIRRHOSIS; MUTATION; REGENERATION; RIBAVIRIN; STEM CELLS; VIRUS REPLICATION;

EID: 84902104150     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i21.6457     Document Type: Article

References (118)

1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538 [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013]
2. Zhang HW, Yin JH, Li YT, Li CZ, Ren H, Gu CY, Wu HY, Liang XS, Zhang P, Zhao JF, Tan XJ, Lu W, Schaefer S, Cao GW. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut 2008; 57: 1713-1720 [PMID: 18755887 DOI: 10.1136/gut.2008.157149]
3. Yin J, Zhang H, He Y, Xie J, Liu S, Chang W, Tan X, Gu C, Lu W, Wang H, Bi S, Cui F, Liang X, Schaefer S, Cao G. Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a community-based study. Cancer Epidemiol Biomarkers Prev 2010; 19: 777-786 [PMID: 20160279 DOI: 10.1158/1055-9965. EPI-09-1001]
4. Yin J, Zhang H, Li C, Gao C, He Y, Zhai Y, Zhang P, Xu L, Tan X, Chen J, Cheng S, Schaefer S, Cao G. Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area. Carcinogenesis 2008; 29: 1685-1691 [PMID: 18192693 DOI: 10.1093/car- cin/bgm301]
5. Chan HL, Wong GL, Tse CH, Chim AM, Yiu KK, Chan HY, Sung JJ, Wong VW. Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. Clin Gastroenterol Hepatol 2009; 7: 1361-1366 [PMID: 19683072 DOI: 10.1016/j.cgh.2009.08.004]
6. Yin J, Xie J, Zhang H, Shen Q, Han L, Lu W, Han Y, Li C, Ni W, Wang H, Cao G. Significant association of different preS mutations with hepatitis B-related cirrhosis or hepatocellular carcinoma. J Gastroenterol 2010; 45: 1063-1071 [PMID: 20419326 DOI: 10.1007/s00535-010-0253-1]
7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539 [PMID: 17256718 DOI: 10.1002/hep.21513]
8. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973 [PMID: 16149085 DOI: 10.1002/hep.20819]
9. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46: 1350-1356 [PMID: 17680653 DOI: 10.1002/hep.21826]
10. Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, Chen PJ, You SL, Wang LY, Chen WJ, Chen CJ. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol 2010; 28: 4587-4593 [PMID: 20855826 DOI: 10.1200/JCO.2010.29.1500]
11. Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, Jiang J, Sun Y, Yang R, Li H, Zhang H, Gong Z, Zhang L, Zhao L, Dou X, Niu J, You H, Chen Z, Ning Q, Gong G, Wu S, Ji W, Mao Q, Tang H, Li S, Wei S, Sun J, Jiang J, Lu L, Jia J, Zhuang H. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2014; 29: 545-553 [PMID: 24090188 DOI: 10.1111/jgh.12398]
12. Deng Y, Du Y, Zhang Q, Han X, Cao G. Human cytidine deaminases facilitate hepatitis B virus evolution and link inflammation and hepatocellular carcinoma. Cancer Lett 2014; 343: 161-171 [PMID: 24120759 DOI: 10.1016/j.canlet.2013.09.041]
13. Lee J, Wu CC, Lee KJ, Chuang TH, Katakura K, Liu YT, Chan M, Tawatao R, Chung M, Shen C, Cottam HB, Lai MM, Raz E, Carson DA. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci USA 2006; 103: 1828-1833 [PMID: 16446426 DOI: 10.1073/pnas.0510801103]
14. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303: 1529-1531 [PMID: 14976261 DOI: 10.1126/science.1093616]
15. Chang J, Block TM, Guo JT. The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res 2012; 96: 405-413 [PMID: 23072881 DOI: 10.1016/j.antiviral.2012.10.001]
16. Karimi-Googheri M, Daneshvar H, Nosratabadi R, Zare-Bidaki M, Hassanshahi G, Ebrahim M, Arababadi MK, Kennedy D. Important roles played by TGF-β in hepatitis B infection. J Med Virol 2014; 86: 102-108 [PMID: 24009084 DOI: 10.1002/jmv.23727]
17. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-1332 [PMID: 17952090 DOI: 10.1038/nm1663]
18. Watanabe A, Hashmi A, Gomes DA, Town T, Badou A, Flavell RA, Mehal WZ. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007; 46: 1509-1518 [PMID: 17705260 DOI: 10.1002/hep.21867]
19. García-Sastre A, Biron CA. Type 1 interferons and the virus- host relationship: a lesson in détente. Science 2006; 312: 879-882 [PMID: 16690858 DOI: 10.1126/science.1125676]
20. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8: 559-568 [PMID: 18575461 DOI: 10.1038/nri2314]
21. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449: 819-826 [PMID: 17943118 DOI: 10.1038/nature06246]
22. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-435 [PMID: 18650913 DOI: 10.1038/nature07201]
23. Bode JG, Brenndörfer ED, Häussinger D. Hepatitis C virus (HCV) employs multiple strategies to subvert the host innate antiviral response. Biol Chem 2008; 389: 1283-1298 [PMID: 18713016 DOI: 10.1515/BC.2008.147]
24. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76 [PMID: 12477811 DOI: 10.1128/JVI.77.1.68-76.2003]
25. Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, Bertoletti A, Maini MK. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007; 204: 667-680 [PMID: 17353365 DOI: 10.1084/jem.20061287]
26. Shin EC, Seifert U, Kato T, Rice CM, Feinstone SM, Kloetzel PM, Rehermann B. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest 2006; 116: 3006-3014 [PMID: 17039255 DOI: 10.1172/JCI2983]
27. Gremion C, Grabscheid B, Wölk B, Moradpour D, Reichen J, Pichler W, Cerny A. Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol 2004; 78: 2152-2157 [PMID: 14747581 DOI: 10.1128/JVI.78.4.2152-2157.2004]
28. Larrubia JR, Benito-Martínez S, Calvino M, Sanz-de-Villalobos E, Parra-Cid T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol 2008; 14: 7149-7159 [PMID: 19084927 DOI: 10.3748/wjg.14.7149]
29. Nattermann J, Schneiders AM, Leifeld L, Langhans B, Schulz M, Inchauspé G, Matz B, Brackmann HH, Houghton M, Sauerbruch T, Spengler U. Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). J Hepatol 2005; 42: 499-504 [PMID: 15763336 DOI: 10.1016/j.jhep.2004.12.018]
30. Yan ZH, Fan Y, Wang XH, Mao Q, Deng GH, Wang YM. Relationship between HLA-DR gene polymorphisms and outcomes of hepatitis B viral infections: a meta-analysis. World J Gastroenterol 2012; 18: 3119-3128 [PMID: 22791948 DOI: 10.3748/wjg.v18.i24.3119]
31. Cangussu LO, Teixeira R, Campos EF, Rampim GF, Mingoti SA, Martins-Filho OA, Gerbase-DeLima M. HLA class II alleles and chronic hepatitis C virus infection. Scand J Immunol 2011; 74: 282-287 [PMID: 21535077 DOI: 10.1111/j.1365-3083.2011.02568.x]
32. Lazarevic I, Djordjevic J, Cupic M, Karalic D, Delic D, Svirtlih N, Simonovic J, Svorcan P, Milic N, Jovanovic T. The influence of single and combined IL28B polymorphisms on response to treatment of chronic hepatitis C. J Clin Virol 2013; 58: 254-257 [PMID: 23831131 DOI: 10.1016/j.jcv.2013.06.014]
33. Ezzikouri S, Alaoui R, Rebbani K, Brahim I, Fakhir FZ, Nadir S, Diepolder H, Khakoo SI, Thursz M, Benjelloun S. Genetic variation in the interleukin-28B gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patients. PLoS One 2013; 8: e54793 [PMID: 23358556 DOI: 10.1371/journal.pone.0054793]
34. Sarobe P, Lasarte JJ, Casares N, López-Díaz de Cerio A, Baixeras E, Labarga P, García N, Borrás-Cuesta F, Prieto J. Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol 2002; 76: 5062-5070 [PMID: 11967322 DOI: 10.1128/JVI.76.10.5062- 5070.2002]
35. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, Hanson HL, Steinberg JP, Masopust D, Wherry EJ, Altman JD, Rouse BT, Freeman GJ, Ahmed R, Grakoui A. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007; 81: 2545-2553 [PMID: 17182670 DOI: 10.1128/JVI.02021-06]
36. Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 2007; 81: 9249-9258 [PMID: 17567698 DOI: 10.1128/JVI.00409-07]
37. Radziewicz H, Ibegbu CC, Hon H, Osborn MK, Obideen K, Wehbi M, Freeman GJ, Lennox JL, Workowski KA, Hanson HL, Grakoui A. Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection. J Virol 2008; 82: 9808-9822 [PMID: 18667503 DOI: 10.1128/JVI.01075-08]
38. Yao ZQ, Eisen-Vandervelde A, Waggoner SN, Cale EM, Hahn YS. Direct binding of hepatitis C virus core to gC1qR on CD4+ and CD8+ T cells leads to impaired activation of Lck and Akt. J Virol 2004; 78: 6409-6419 [PMID: 15163734 DOI: 10.1128/JVI.78.12.6409-6419.2004]
39. Yao ZQ, Shata MT, Tricoche N, Shan MM, Brotman B, Pfahler W, Hahn YS, Prince AM. gC1qR expression in chimpanzees with resolved and chronic infection: potential role of HCV core/gC1qR-mediated T cell suppression in the outcome of HCV infection. Virology 2006; 346: 324-337 [PMID: 16368125 DOI: 10.1016/j.virol.2005.11.020]
40. Brenndörfer ED, Brass A, Söderholm J, Frelin L, Aleman S, Bode JG, Sällberg M. Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production. Gut 2012; 61: 589-596 [PMID: 21813471 DOI: 10.1136/gut.2010.232116]
41. Riezu-Boj JI, Larrea E, Aldabe R, Guembe L, Casares N, Galeano E, Echeverria I, Sarobe P, Herrero I, Sangro B, Prieto J, Lasarte JJ. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. J Hepatol 2011; 54: 422-431 [PMID: 21129807 DOI: 10.1016/j.jhep.2010.07.014]
42. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007; 7: 875-888 [PMID: 17948021 DOI: 10.1038/nri2189]
43. Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer 2012; 48: 1977-1987 [PMID: 22325840 DOI: 10.1016/j.ejca.2012.01.015]
44. Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, Cao GW. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol 2011; 17: 4258-4270 [PMID: 22090781 DOI: 10.3748/wjg.v17.i38.4258]
45. Bièche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, Bedossa P, Valla DC, Marcellin P, Vidaud M. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 2005; 332: 130-144 [PMID: 15661146 DOI: 10.1016/j.virol.2004.11.009]
46. Takahara Y, Takahashi M, Zhang QW, Wagatsuma H, Mori M, Tamori A, Shiomi S, Nishiguchi S. Serial changes in expression of functionally clustered genes in progression of liver fibrosis in hepatitis C patients. World J Gastroenterol 2008; 14: 2010-2022 [PMID: 18395900 DOI: 10.3748/wjg.14.2010]
47. Utsunomiya T, Okamoto M, Hashimoto M, Yoshinaga K, Shiraishi T, Tanaka F, Mimori K, Inoue H, Watanabe G, Barnard GF, Mori M. A gene-expression signature can quantify the degree of hepatic fibrosis in the rat. J Hepatol 2004; 41: 399-406 [PMID: 15336442 DOI: 10.1016/j.jhep.2004.05.015]
48. Tacke F, Luedde T, Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 2009; 36: 4-12 [PMID: 18600481 DOI: 10.1007/s12016-008-8091-0]
49. Hösel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning CJ, Langenkamp A, Falk C, Büning H, Rose-John S, Protzer U. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009; 50: 1773-1782 [PMID: 19937696 DOI: 10.1002/hep.23226]
50. Borkham-Kamphorst E, Stoll D, Gressner AM, Weiskirchen R. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem Biophys Res Commun 2004; 321: 413-423 [PMID: 15358192 DOI: 10.1016/j.bbrc.2004.06.153]
51. Wietzke-Braun P, Manhardt LB, Rosenberger A, Uy A, Ramadori G, Mihm S. Spontaneous elimination of hepatitis C virus infection: a retrospective study on demographic, clinical, and serological correlates. World J Gastroenterol 2007; 13: 4224-4229 [PMID: 17696252]
52. Bowen DG, Walker CM. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 2005; 201: 1709-1714 [PMID: 15939787 DOI: 10.1084/jem.20050808]
53. Fernandez J, Taylor D, Morhardt DR, Mihalik K, Puig M, Rice CM, Feinstone SM, Major ME. Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity. J Virol 2004; 78: 9782-9789 [PMID: 15331711 DOI: 10.1128/JVI.78.18.9782-9789.2004]
54. Osiowy C, Giles E, Tanaka Y, Mizokami M, Minuk GY. Molecular evolution of hepatitis B virus over 25 years. J Virol 2006; 80: 10307-10314 [PMID: 17041211 DOI: 10.1128/JVI.00996-06]
55. Peng ZG, Zhao ZY, Li YP, Wang YP, Hao LH, Fan B, Li YH, Wang YM, Shan YQ, Han YX, Zhu YP, Li JR, You XF, Li ZR, Jiang JD. Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus. Hepatology 2011; 53: 1080-1089 [PMID: 21480314 DOI: 10.1002/hep.24160]
56. Vartanian JP, Henry M, Marchio A, Suspène R, Aynaud MM, Guétard D, Cervantes-Gonzalez M, Battiston C, Mazzaferro V, Pineau P, Dejean A, Wain-Hobson S. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog 2010; 6: e1000928 [PMID: 20523896 DOI: 10.1371/journal.ppat.1000928]
57. Yin J, Xie J, Liu S, Zhang H, Han L, Lu W, Shen Q, Xu G, Dong H, Shen J, Zhang J, Han J, Wang L, Liu Y, Wang F, Zhao J, Zhang Q, Ni W, Wang H, Cao G. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol 2011; 106: 81-92 [PMID: 20959817 DOI: 10.1038/ajg.2010.399]
58. Zhang Q, Yin J, Zhang Y, Deng Y, Ji X, Du Y, Pu R, Han Y, Zhao J, Han X, Zhang H, Cao G. HLA-DP polymorphisms affect the outcomes of chronic hepatitis B virus infections, possibly through interacting with viral mutations. J Virol 2013; 87: 12176-12186 [PMID: 24006435 DOI: 10.1128/JVI.02073-13]
59. Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, Lu SN, Changchien CS. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 2007; 133: 1466-1474 [PMID: 17915220 DOI: 10.1053/j.gastro.2007.09.002]
60. Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009; 101: 1066-1082 [PMID: 19574418 DOI: 10.1093/jnci/djp180]
61. Tamori A, Kawada N. HLA class II associated with outcomes of hepatitis B and C infections. World J Gastroenterol 2013; 19: 5395-5401 [PMID: 24023482 DOI: 10.3748/wjg.v19. i33.5395]
62. Kitab B, Essaid El Feydi A, Afifi R, Trepo C, Benazzouz M, Essamri W, Zoulim F, Chemin I, Alj HS, Ezzikouri S, Benjelloun S. Variability in the precore and core promoter regions of HBV strains in Morocco: characterization and impact on liver disease progression. PLoS One 2012; 7: e42891 [PMID: 22905181 DOI: 10.1371/journal.pone.0042891]
63. Lee JH, Han KH, Lee JM, Park JH, Kim HS. Impact of hepatitis B virus (HBV) x gene mutations on hepatocellular carcinoma development in chronic HBV infection. Clin Vaccine Immunol 2011; 18: 914-921 [PMID: 21490166 DOI: 10.1128/CVI.00474-10]
64. Brenner DA, Kisseleva T, Scholten D, Paik YH, Iwaisako K, Inokuchi S, Schnabl B, Seki E, De Minicis S, Oesterreicher C, Taura K. Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair 2012; 5 Suppl 1: S17 [PMID: 23259769 DOI: 10.1186/1755-1536-5-S1-S17]
65. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172 [PMID: 18195085 DOI: 10.1152/physrev.00013.2007]
66. Jiang JX, Mikami K, Shah VH, Torok NJ. Leptin induces phagocytosis of apoptotic bodies by hepatic stellate cells via a Rho guanosine triphosphatase-dependent mechanism. Hepatology 2008; 48: 1497-1505 [PMID: 18925608 DOI: 10.1002/hep.22515]
67. Zhao G, Hatting M, Nevzorova YA, Peng J, Hu W, Boekschoten MV, Roskams T, Muller M, Gassler N, Liedtke C, Davis RJ, Cubero FJ, Trautwein C. Jnk1 in murine hepatic stellate cells is a crucial mediator of liver fibrogenesis. Gut 2013; Epub ahead of print [PMID: 24037431 DOI: 10.1136/gutjnl-2013-305507]
68. Kluwe J, Pradere JP, Gwak GY, Mencin A, De Minicis S, Osterreicher CH, Colmenero J, Bataller R, Schwabe RF. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 2010; 138: 347-359 [PMID: 19782079 DOI: 10.1053/j.gastro.2009.09.015]
69. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007; 117: 539-548 [PMID: 17332881 DOI: 10.1172/JCI30542]
70. Forbes SJ, Parola M. Liver fibrogenic cells. Best Pract Res Clin Gastroenterol 2011; 25: 207-217 [PMID: 21497739 DOI: 10.1016/j.bpg.2011.02.006]
71. Shrivastava S, Mukherjee A, Ray R, Ray RB. Hepatitis C virus induces interleukin-1β (IL-1β)/IL-18 in circulatory and resident liver macrophages. J Virol 2013; 87: 12284-12290 [PMID: 24006444 DOI: 10.1128/JVI.01962-13]
72. Sica A, Invernizzi P, Mantovani A. Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology 2014; 59: 2034-2042 [PMID: 24115204 DOI: 10.1002/hep.26754]
73. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999; 19: 129-140 [PMID: 10422196 DOI: 10.1055/s-2007-1007105]
74. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R, Iredale JP. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56-65 [PMID: 15630444 DOI: 10.1172/JCI200522675]
75. Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol 2012; 1: 174-183 [PMID: 24175223 DOI: 10.5501/wjv.v1.i6.174]
76. Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008; 14: 6902-6910 [PMID: 19058323 DOI: 10.3748/wjg.14.6902]
77. Yuen MF, Lai CL. Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol 2011; 26 Suppl 1: 138-143 [PMID: 21199525 DOI: 10.1111/j.1440-1746.2010.06545.x]
78. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/hep.23190]
79. Mutimer DJ, Lok A. Management of HBV- and HCV-induced end stage liver disease. Gut 2012; 61 Suppl 1: 59-67 [PMID: 22504920 DOI: 10.1136/gutjnl-2012-302076]
80. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57: 442-450 [PMID: 22504333 DOI: 10.1016/j.jhep.2012.02.033]
81. Roche B, Samuel D. Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients. Clin Liver Dis 2013; 17: 451-473 [PMID: 23905816 DOI: 10.1016/j.cld.2013.05.003]
82. Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 2007; 1: 267-273 [PMID: 19669348 DOI: 10.1007/s12072-007-5001-0]
83. Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health 2010; 13: 934-945 [PMID: 20825624 DOI: 10.1111/j.1524-4733.2010.00777.x]
84. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, openlabel study. Hepatology 2011; 54: 91-100 [PMID: 21503940 DOI: 10.1002/hep.24361]
85. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72 [PMID: 21254162 DOI: 10.1002/hep.23952]
86. Huang Y, Wu H, Wu S, Fu D, Ma Y, Shen X. A meta-analysis of nucleos(t)ide analogues in patients with decompensated cirrhosis due to hepatitis B. Dig Dis Sci 2013; 58: 815-823 [PMID: 23053891 DOI: 10.1007/s10620-012-2414-y]
87. Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R, Tanwandee T, Chutaputti A, Yurdaydin C, Bao W, Avila C, Trylesinski A. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012; 19: 732-743 [PMID: 22967105 DOI: 10.1111/j.1365-2893.2012.01600.x]
88. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-182 [PMID: 20006394 DOI: 10.1016/j.jhep.2009.11.007]
89. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, Samuel D, Zeuzem S, Villeneuve JP, Arterburn S, Borroto-Esoda K, Brosgart C, Chuck S. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final longterm results. Liver Transpl 2007; 13: 349-360 [PMID: 17326221 DOI: 10.1002/lt.20981]
90. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-727 [PMID: 12198698]
91. Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19: 6278-6283 [PMID: 24115827 DOI: 10.3748/wjg.v19.i37.6278]
92. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
93. Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009; 104: 1802-1829 [PMID: 19455106 DOI: 10.1038/ajg.2009.191]
94. Murray KF, Carithers RL. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-1432 [PMID: 15880505 DOI: 10.1002/hep.20704]
95. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982 [PMID: 12324553 DOI: 10.1056/NEJMoa020047]
96. European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012; 32 Suppl 1: 2-8 [PMID: 22212565 DOI: 10.1111/j.1478-3231.2011.02703.x]
97. Ponziani FR, Annicchiarico EB, Siciliano M, D'Aversa F, Pompili M, Gasbarrini A. Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation. World J Gastroenterol 2013; 19: 3255-3262 [PMID: 23745027 DOI: 10.3748/wjg.v19.i21.3255]
98. Marinho RT, Barreira DP. Hepatitis C, stigma and cure. World J Gastroenterol 2013; 19: 6703-6709 [PMID: 24187444 DOI: 10.3748/wjg.v19.i40.6703]
99. Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Lawitz E, Zhou A, Bourque M, Bhanja S, Strizki J, Barnard RJ, Hwang PM, Dinubile MJ, Mobashery N. Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis. Clin Gastroenterol Hepatol 2013; Epub ahead of print [PMID: 24120953 DOI: 10.1016/j.cgh.2013.09.067]
100. Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology 2014; 146: 442-522 [PMID: 24126097 DOI: 10.1053/j.gastro.2013.10.012]
101. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801 [PMID: 19759533 DOI: 10.1038/nature08463]
102. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]
103. Luo Y, Jin C, Ling Z, Mou X, Zhang Q, Xiang C. Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis. Gene 2013; 513: 292-296 [PMID: 23142377 DOI: 10.1016/j.gene.2012.10.030]
104. Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 1110-1125 [PMID: 22659520 DOI: 10.1016/j.jhep.2012.05.016]
105. Dultz G, Seelhof M, Herrmann E, Welker MW, Friedrich-Rust M, Teuber G, Kronenberger B, von Wagner M, Vermehren J, Sarrazin C, Zeuzem S, Hofmann WP. Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis. PLoS One 2013; 8: e71262 [PMID: 23936497 DOI: 10.1371/journal.pone.0071262]
106. Zhang Z, Wang FS. Stem cell therapies for liver failure and cirrhosis. J Hepatol 2013; 59: 183-185 [PMID: 23353868 DOI: 10.1016/j.jhep.2013.01.018]
107. Forbes SJ, Newsome PN. New horizons for stem cell therapy in liver disease. J Hepatol 2012; 56: 496-499 [PMID: 21798218 DOI: 10.1016/j.jhep.2011.06.022]
108. Yu B, He ZY, You P, Han QW, Xiang D, Chen F, Wang MJ, Liu CC, Lin XW, Borjigin U, Zi XY, Li JX, Zhu HY, Li WL, Han CS, Wangensteen KJ, Shi Y, Hui LJ, Wang X, Hu YP. Reprogramming fibroblasts into bipotential hepatic stem cells by defined factors. Cell Stem Cell 2013; 13: 328-340 [PMID: 23871605 DOI: 10.1016/j.stem.2013.06.017]
109. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27: 1421-1432 [PMID: 19489103 DOI: 10.1002/stem.68]
110. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-736 [PMID: 19172693 DOI: 10.1038/nri2395]
111. Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, Cai T, Chen W, Sun L, Shi S. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 2012; 10: 544-555 [PMID: 22542159 DOI: 10.1016/j.stem.2012.03.007]
112. Huang P, He Z, Ji S, Sun H, Xiang D, Liu C, Hu Y, Wang X, Hui L. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 2011; 475: 386-389 [PMID: 21562492 DOI: 10.1038/nature10116]
113. Theise ND, Nimmakayalu M, Gardner R, Illei PB, Morgan G, Teperman L, Henegariu O, Krause DS. Liver from bone marrow in humans. Hepatology 2000; 32: 11-16 [PMID: 10869283]
114. Alison MR, Poulsom R, Jeffery R, Dhillon AP, Quaglia A, Jacob J, Novelli M, Prentice G, Williamson J, Wright NA. Hepatocytes from non-hepatic adult stem cells. Nature 2000; 406: 257 [PMID: 10917519 DOI: 10.1038/35018642]
115. Okamoto R, Yajima T, Yamazaki M, Kanai T, Mukai M, Okamoto S, Ikeda Y, Hibi T, Inazawa J, Watanabe M. Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat Med 2002; 8: 1011-1017 [PMID: 12195435 DOI: 10.1038/nm755]
116. Thomas JA, Pope C, Wojtacha D, Robson AJ, Gordon-Walker TT, Hartland S, Ramachandran P, Van Deemter M, Hume DA, Iredale JP, Forbes SJ. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology 2011; 53: 2003-2015 [PMID: 21433043 DOI: 10.1002/hep.24315]
117. Huang CK, Lee SO, Lai KP, Ma WL, Lin TH, Tsai MY, Luo J, Chang C. Targeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis. Hepatology 2013; 57: 1550-1563 [PMID: 23150236 DOI: 10.1002/hep.26135]
118. Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, Uchida K, Yamasaki T, Fujii Y, Okita K, Sakaida I. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 2006; 24: 2292-2298 [PMID: 16778155 DOI: 10.1634/stemcells.2005-0542]